Time evolution of cytokine profiles associated with mortality in COVID-19 hospitalized patients

• DOI: 10.3389/fimmu.2022.946730
• Publication Date: 2022-09-27T05:38:20Z
• Authors: Laura Sánchez-de ...; Óscar Gorgojo-Gal...; Inmaculada Fierro; Ana María Martíne...; Guillermo Sarment...; Rocío Gutiérrez-B...; María Teresa Pela...; Elisa Álvarez-Fuente; Esther Gómez-Sánchez; Eduardo Tamayo; Álvaro Tamayo-Vel...; Marta Martín-Fern...
• Keywords: Interleukin-15; 0301 basic medicine; SARS-CoV-2; Brain-Derived Neurotrophic Factor; Immunology; Interleukin-18; hospitalized patients; COVID-19; RC581-607; mortality; principal component analysis - PCA; Interleukin-12; cytokines; 3. Good health; 03 medical and health sciences; Cytokines; Humans; RNA, Viral; Immunologic diseases. Allergy; Chemokines

Background High cytokine levels have been associated with severe COVID-19 disease. Although many studies performed, not of them include combinatorial analysis profiles through time. In this study we investigate the association certain and its evolution, mortality in SARS-CoV2 infection hospitalized patients. Methods Serum concentration 45 cytokines was determined 28 controls at day admission 108 patients disease first, third sixth admission. A principal component (PCA) performed to characterize time survival Results At non-survivors present significantly higher IL-1α VEGFA (PC3) but follow up. However, combination HGF, MCP-1, IL-18, eotaxine, SCF (PC2) are all three time-points presenting an increased trend group On other hand, BDNF, IL-12 IL-15 (PC1) reduced points a decreasing time, though protective factor. The combined prediction accuracy PC3 1 PC1 PC2 6 is 89.00% (p<0.001). Conclusions Hypercytokinemia hallmark relevant differences between survivors can be early observed. Combinatorial serum chemokines contribute risk assessment optimize therapeutic strategies. Three clusters identified as independent markers or factors COVID mortality.